137 related articles for article (PubMed ID: 38158897)
1. [Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease].
Goncharov AA; Sasunova AN; Pilipenko VI; Isakov VA
Ter Arkh; 2023 Oct; 95(8):641-647. PubMed ID: 38158897
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
4. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
5. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
6. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis.
Sourianarayanane A; McCullough AJ
Clin Res Hepatol Gastroenterol; 2022; 46(7):101997. PubMed ID: 35842111
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
Ding Y; Jiang L; Wang Q; Zhao W; Zhou X; Lu J; Tian T; Yu C; Xu X; Guo W; Zhang Q; Song C
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101951. PubMed ID: 35605893
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
11. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
[TBL] [Abstract][Full Text] [Related]
13. Clinical Performance of Transient Elastography With Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents With Known or Suspected Fatty Liver Disease.
P V Alves V; T Trout A; Dewit M; Mouzaki M; Arce-Clachar AC; S Bramlage K; R Dillman J; A Xanthakos S
Child Obes; 2023 Oct; 19(7):461-469. PubMed ID: 36269577
[No Abstract] [Full Text] [Related]
14. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
15. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
[TBL] [Abstract][Full Text] [Related]
18. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
19. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
20. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
